Precigen (NASDAQ:PGEN) Stock Rating Reaffirmed as Buy by B. Riley Financial

Precigen (NASDAQ:PGEN – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities researchers at B. Riley Financial in a research report issued on Monday, Benzinga reports. They currently have a $11.00 price objective on the biotechnology company’s stock, down from their prior price objective of $12.00. B. Riley Financial‘s target price would indicate a potential upside of 156.41% from the stock’s previous close.

A number of other equities research analysts have also recently commented on the stock. Zacks Research cut shares of Precigen from a “strong-buy” rating to a “hold” rating in a report on Monday, October 5th. Citizens Jmp increased their price objective on Precigen from $11.00 to $12.00 and gave the company a “market outperform” rating in a report on Thursday, November 5th. Raymond James Financial set a $12.00 price objective on Precigen in a report on Thursday, November 5th. Wall Street Zen raised Precigen from a “buy” rating to a “strong-buy” rating in a research report on Sunday, November 8th. Finally, Citigroup reissued a “market outperform” rating on shares of Precigen in a research report on Thursday, November 5th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Precigen has an average rating of “Moderate Buy” and a consensus target price of $13.25.

View Our Latest Report on PGEN

Precigen Trading Down 0.2%

Shares of PGEN stock opened at $4.29 on Monday. Precigen has a 52-week low of $3.04 and a 52-week high of $8.98. The company has a debt-to-equity ratio of 1.12, a quick ratio of 4.83 and a current ratio of 5.58. The company has a 50-day simple moving average of $6.63 and a two-hundred day simple moving average of $5.28. The company has a market capitalization of $1.54 billion, a price-to-earnings ratio of 42.90 and a beta of 1.01.

Precigen (NASDAQ:PGEN – Get Free Report) last posted its earnings results on Wednesday, November 4th. The biotechnology company reported $0.08 EPS for the quarter, topping the consensus estimate of $0.06 by $0.02. Precigen had a net margin of 15.55% and a return on equity of 57.93%. The firm had revenue of $74.15 million for the quarter, compared to analysts’ expectations of $71.55 million. During the same quarter last year, the firm earned ($1.06) EPS. The company’s quarterly revenue was up 2437.6% compared to the same quarter last year. Research analysts anticipate that Precigen will post 0.23 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Jeffrey B. Kindler sold 185,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $7.44, for a total transaction of $1,376,400.00. Following the sale, the director owned 17,100 shares of the company’s stock, valued at approximately $127,224. This represents a 91.54% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, COO Rutul R. Shah sold 34,658 shares of the company’s stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $7.50, for a total transaction of $259,935.00. Following the sale, the chief operating officer directly owned 465,012 shares in the company, valued at $3,487,590. This trade represents a 6.94% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 235,000 shares of company stock valued at $1,751,400 over the last 90 days. 41.40% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Patient Capital Management LLC bought a new position in Precigen in the 2nd quarter worth about $108,511,000. BlackRock Inc. purchased a new stake in shares of Precigen in the 2nd quarter valued at about $97,737,000. First Trust Advisors LP boosted its position in shares of Precigen by 30.2% during the 3rd quarter. First Trust Advisors LP now owns 2,623,975 shares of the biotechnology company’s stock valued at $22,461,000 after acquiring an additional 609,316 shares during the last quarter. Bank of America Corp DE bought a new stake in shares of Precigen during the 2nd quarter valued at about $10,536,000. Finally, Wellington Management Group LLP boosted its position in shares of Precigen by 9.2% during the 2nd quarter. Wellington Management Group LLP now owns 555,230 shares of the biotechnology company’s stock valued at $3,165,000 after acquiring an additional 46,796 shares during the last quarter. 33.51% of the stock is owned by institutional investors.

Precigen Company Profile

(Get Free Report)

Precigen, Inc. is a biotechnology company focused on developing gene and cell therapies, including engineered immunotherapies. The company is based in Germantown, Maryland, and its roots include Intrexon, which adopted the Precigen name in 2020. Its approved product, PAPZIMEOS (zopapogene imadenovec-drba), is a gene therapy for adults with recurrent respiratory papillomatosis, a rare condition associated with human papillomavirus types 6 and 11. Precigen is also developing investigational therapies for cancers and other diseases.

Further Reading

Analyst Recommendations for Precigen (NASDAQ:PGEN)

Receive News & Ratings for Precigen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precigen and related companies with MarketBeat.com's FREE daily email newsletter.